Literature DB >> 15342170

Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study.

Johan Sundström1, Jane C Evans, Emelia J Benjamin, Daniel Levy, Martin G Larson, Douglas B Sawyer, Deborah A Siwik, Wilson S Colucci, Peter W F Wilson, Ramachandran S Vasan.   

Abstract

AIMS: Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a key regulator of extracellular matrix degradation. We examined relations of plasma total TIMP-1 to cardiovascular risk factors and echocardiographic left ventricular (LV) structure and function in a community-based sample. METHODS AND
RESULTS: We studied 1069 Framingham Heart Study participants (mean age 56 years, 58% women) free of heart failure and previous myocardial infarction. Plasma TIMP-1 was higher in men compared with women, and increased with age, body mass index and total/HDL-cholesterol ratio, but decreased with alcohol intake. Plasma TIMP-1 was also directly related to smoking, diabetes and use of anti-hypertensive treatment. Adjusting for age, sex and height, plasma TIMP-1 was positively associated with LV mass, wall thickness, relative wall thickness, end-systolic diameter, and left atrial diameter and the risk of having increased LV end-diastolic diameter or increased wall thickness, and negatively correlated with fractional shortening. Additional adjustment for clinical covariates attenuated the relations of plasma TIMP-1 to most echocardiographic measures.
CONCLUSIONS: In our cross-sectional investigation, plasma total TIMP-1 was related to major cardiovascular risk factors and to indices of LV hypertrophy and systolic dysfunction. This raises the possibility that cardiovascular risk factors may influence cardiovascular remodelling via extracellular matrix degradation, which may be reflected in plasma TIMP-1 levels. Copyright 2004 Elsevier Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342170     DOI: 10.1016/j.ehj.2004.05.029

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  53 in total

1.  Tissue Inhibitor of Metalloproteinase-1: Actions beyond Matrix Metalloproteinase Inhibition.

Authors:  Merry L Lindsey; Andriy Yabluchanskiy; Yonggang Ma
Journal:  Cardiology       Date:  2015-08-01       Impact factor: 1.869

Review 2.  Imaging of matrix metalloproteinase activation and left ventricular remodeling.

Authors:  Grace Chung; Albert J Sinusas
Journal:  Curr Cardiol Rep       Date:  2007-04       Impact factor: 2.931

3.  Plasma profiling determinants of matrix homeostasis in paediatric dilated cardiomyopathy.

Authors:  Tain-Yen Hsia; Jeremy M Ringewald; Robert E Stroud; Nadia Roessler; Nidhi Kumar; Scott T Reeves; Francis G Spinale
Journal:  Cardiol Young       Date:  2010-10-27       Impact factor: 1.093

4.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

Review 5.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 6.  Screening for ventricular remodeling.

Authors:  Douglas S Lee; Thomas J Wang; Ramachandran S Vasan
Journal:  Curr Heart Fail Rep       Date:  2006-04

7.  Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).

Authors:  D Dirk Bonnema; Carson S Webb; Weems R Pennington; Robert E Stroud; Amy E Leonardi; Leslie L Clark; Catherine D McClure; Laura Finklea; Francis G Spinale; Michael R Zile
Journal:  J Card Fail       Date:  2007-09       Impact factor: 5.712

8.  Association of carotid artery atherosclerosis with circulating biomarkers of extracellular matrix remodeling: the Framingham Offspring Study.

Authors:  Jose R Romero; Ramachandran S Vasan; Alexa S Beiser; Joseph F Polak; Emelia J Benjamin; Philip A Wolf; Sudha Seshadri
Journal:  J Stroke Cerebrovasc Dis       Date:  2008 Nov-Dec       Impact factor: 2.136

Review 9.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

10.  Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy.

Authors:  Jose María Tolosana; Lluís Mont; Marta Sitges; Antonio Berruezo; Victoria Delgado; Bàrbara Vidal; David Tamborero; Manel Morales; Montserrat Batlle; Eulalia Roig; M Angeles Castel; Félix Pérez-Villa; Miguel Godoy; Josep Brugada
Journal:  Eur J Heart Fail       Date:  2010-04-01       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.